Enriching for tumor-reactive CD8 TIL using CD39/103 markers: Clinical implications

Authors

A Weinberg, Providence

Document Type

Presentation

Publication Date

8-22-2022

Keywords

oregon; portland; chiles

Clinical Institute

Cancer

Department

Oncology

Comments

Cell Therapy Durbility Response Summit; 2022 August 22; Boston, MA.

Recommended Citation

Weinberg, A, "Enriching for tumor-reactive CD8 TIL using CD39/103 markers: Clinical implications" (2022). Articles, Abstracts, and Reports. 6974.
https://digitalcommons.providence.org/publications/6974